score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6806	382.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Putatively Actionable	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	MEL-IPI_Pat168-Normal-SM-5VWIS
Putatively Actionable	Guideline	Guideline		Copy Number	MET	Amplification				0.0	0.0		Putatively Actionable	Crizotinib	Targeted therapy	Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Putatively Actionable	Gefitinib	Targeted therapy	Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				MET Amplification	0.0	MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2A Deletion		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat168		
Investigate Actionability - Low			Clinical evidence	Somatic Variant	ASXL1	Missense	p.G680S	0.0612	49.0	0.0	0.0														Investigate Actionability - Low	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				ASXL1 p.G680S (Missense)		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	MEL-IPI_Pat168-Normal-SM-5VWIS
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.K477N	0.3182	44.0	0.0	0.0																			0				NTRK3 p.K477N (Missense)		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	MEL-IPI_Pat168-Normal-SM-5VWIS
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																			0				ESRP1 Amplification		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	
Biologically Relevant				Copy Number	FGFR3	Deletion				0.0	0.0																			0				FGFR3 Deletion		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	
Biologically Relevant				Copy Number	TACC3	Deletion				0.0	0.0																			0				TACC3 Deletion		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	
Biologically Relevant				Copy Number	MLH3	Deletion				0.0	0.0																			0				MLH3 Deletion		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	
Biologically Relevant				Copy Number	POLE2	Deletion				0.0	0.0																			0				POLE2 Deletion		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	
Biologically Relevant				Copy Number	AKT1	Deletion				0.0	0.0																			0				AKT1 Deletion		MEL-IPI_Pat168	MEL-IPI_Pat168-Tumor-SM-7A15I	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification, POLE2 Deletion																							0				Supporting variants: ESRP1 Amplification, POLE2 Deletion		MEL-IPI_Pat168		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.212																							0				COSMIC Signature 1 (21%)		MEL-IPI_Pat168		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.491																							0				COSMIC Signature 7 (49%)		MEL-IPI_Pat168		
